

CERTIFICATE OF ANALYSIS

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

TB - VAPE (CONCENTRATE) // PRODUCED: JAN 20, 2026

CLIENT: TASTEFULLY BAKED // BATCH: PASS



BATCH NO.: TB - RP43 ¹
MATRIX: CONCENTRATE ²
SAMPLE ID: NAL-260113-042
COLLECTED ON: JAN 13, 2026
RECEIVED ON: JAN 13, 2026
SAMPLE SIZE: 1.5 ML ¹
SAMPLED BY: JANELLE LAPLANTE
RECEIVED BY: ALEX ERAMO

¹ ENTERED BY CLIENT, ² ENTERED BY LAB

CANNABINOID OVERVIEW

Δ⁹-THC:	66.2 %
CBG:	2.34 %
TOTAL CANNABINOIDS:	69.9 %

BATCH RESULT: PASS

POTENCY	TESTED
SOLVENTS	PASS
TERPENES	TESTED

CAN.1: POTENCY & CANNABINOID PROFILE BY HPLC-UV PREPARATION: JAN 15, 2026 // ANALYSIS: JAN 16, 2026

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (%)	PASS/FAIL
CBC	1.35 %	13.5 mg/g	0.189/0.377	N/A	
CBCA		ND	0.189/0.377	N/A	
CBD		ND	0.189/0.377	N/A	
CBDA		ND	0.189/0.377	N/A	
CBDV		ND	0.189/0.377	N/A	
CBDVA	ND	ND	0.189/0.377	N/A	
CBG	2.34 %	23.4 mg/g	0.189/0.377	N/A	
CBGA		ND	0.189/0.377	N/A	
CBL		ND	0.377/0.377	N/A	
CBLA		ND	0.189/0.377	N/A	
CBN		ND	0.189/0.377	N/A	

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (%)	PASS/FAIL
CBNA		ND	ND	0.189/0.377	N/A
Δ ⁸ -THC		ND	ND	0.377/0.377	N/A
Δ ⁸ -THCA		ND	ND	0.377/0.377	N/A
Δ ⁹ -THC	66.2 %	662 mg/g	0.189/0.377	N/A	
Δ ¹⁰ -THC	ND	ND	0.189/0.377	N/A	
EXO-THC	ND	ND	0.377/0.377	N/A	
THCA	ND	ND	0.377/0.377	N/A	
THCV	< LOQ	< LOQ	0.189/0.377	N/A	
THCVA	ND	ND	0.189/0.377	N/A	
TOTAL THC**	66.2 %	662 mg/g		N/A	
TOTAL CBD**	ND	ND		N/A	

** TOTAL THC = (THCA X 0.877) + DELTA-9-THC

** TOTAL CBD = (CBDA X 0.877) + CBD

Reported on an as received basis.

1000 µg/g = 1 mg/g



AUTHORIZED BY:
ZACHARY SMITH
LABORATORY MANAGER, NOVA
ANALYTIC LABS
JAN 20, 2026

ANALYTE	AMT	AMT	LOD/LOQ (mg/g)	PASS/FAIL
TOTAL TERPENES	10.1 %	101 mg/g		N/A
D-LIMONENE	2.68 %	26.8 mg/g	0.132/0.264	N/A
β-CARYOPHYLLENE	2.55 %	25.5 mg/g	0.132/0.264	N/A
β-MYRCENE	1.44 %	14.4 mg/g	0.132/0.264	N/A
α-HUMULENE	0.885 %	8.85 mg/g	0.132/0.264	N/A
LINALOOL	0.531 %	5.31 mg/g	0.132/0.264	N/A
α-PINENE	0.408 %	4.08 mg/g	0.132/0.264	N/A
β-PINENE	0.322 %	3.22 mg/g	0.132/0.264	N/A
ENDO FENCHYL ALCOHOL	0.291 %	2.91 mg/g	0.132/0.264	N/A
α-BISABOLOL	0.242 %	2.42 mg/g	0.132/0.264	N/A
TERPINEOL	0.191 %	1.91 mg/g	0.132/0.264	N/A
FARNESENE	0.183 %	1.83 mg/g	0.132/0.264	N/A
TRANS-β-OCIMENE	0.168 %	1.68 mg/g	0.132/0.264	N/A
CAMPHENE	0.0660 %	0.660 mg/g	0.132/0.264	N/A
TERPINOLENE	0.0426 %	0.426 mg/g	0.132/0.264	N/A
BORNEOL	0.0422 %	0.422 mg/g	0.132/0.264	N/A
GUAIOL	0.0372 %	0.372 mg/g	0.132/0.264	N/A
CARYOPHYLLENE OXIDE	0.0305 %	0.305 mg/g	0.132/0.264	N/A
(-)-VERBENONE	ND	ND	0.132/0.264	N/A
2-PIPERIDONE	ND	ND	0.132/0.264	N/A
α-CEDRENE	ND	ND	0.132/0.264	N/A
α-PHELLANDRENE	ND	ND	0.132/0.264	N/A
α-TERPINENE	ND	ND	0.132/0.264	N/A
α-THUJONE	ND	ND	0.132/0.264	N/A
CAMPHOR	ND	ND	0.132/0.264	N/A
CARVACROL	ND	ND	0.132/0.264	N/A
CEDROL	ND	ND	0.132/0.264	N/A
CIS-β-OCIMENE	ND	ND	0.132/0.264	N/A
CITRAL	ND	ND	0.132/0.264	N/A
CITRONELLOL	ND	ND	0.132/0.264	N/A

RSOL.1: RESIDUAL SOLVENTS, POISONS AND TOXINS BY HEADSPACE GC-MS
PREPARATION: JAN 14, 2026 // ANALYSIS: JAN 19, 2026

ANALYTE	LIMIT	AMT (µg/g)	LOD/LOQ (µg/g)	PASS/FAIL
1,2-DICHLOROETHANE	1 µg/g	ND	0.437/0.873	PASS
ACETONE	5000 µg/g	ND	43.7/87.3	PASS
ACETONITRILE	410 µg/g	ND	43.7/87.3	PASS
BENZENE	1 µg/g	ND	0.437/0.873	PASS
BUTANE	5000 µg/g	5.00	0.873/2.18	PASS
CHLOROFORM	1 µg/g	ND	0.437/0.873	PASS
ETHANOL	5000 µg/g	ND	43.7/87.3	PASS
ETHYL ACETATE	5000 µg/g	ND	8.73/17.5	PASS
ETHYLENE OXIDE	1 µg/g	ND	0.437/0.873	PASS
ETHYL ETHER	5000 µg/g	ND	8.73/17.5	PASS
HEPTANE	5000 µg/g	ND	8.73/17.5	PASS

NOTES

ZACHARY SMITH
JAN 20, 2026

POTENCY & CANNABINOID PROFILE BY HPLC-UV
THE STANDARD LAB UNCERTAINTY FOR POTENCY IS 5% OF THE REPORTED VALUE.

PRODUCT IMAGES



* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

ALL TESTS WERE PERFORMED IN ACCORDANCE WITH THE RULES AND REGULATIONS SET FORTH IN THE MAINE ADULT USE PROGRAM. LABORATORY SAMPLING PROTOCOLS ARE GOVERNED BY THE OCP'S SAMPLING GUIDANCE DOCUMENTS. ALL INFORMATION PROVIDED BY THE CLIENT, INCLUDING SELF SAMPLING, MUST BE ACCURATE AND ADHERE TO THE SAME RULES AND



REGULATIONS. HOWEVER, CLIENT PROVIDED INFORMATION, INCLUDING SAMPLING, IS ULTIMATELY THE RESPONSIBILITY OF THE PROVIDING LICENSEE, REGISTERED CAREGIVER, PATIENT OR THE LIKE AND FAILURE TO FOLLOW SAID PROTOCOLS COULD LEAD TO ERRONEOUS TEST RESULTS. NOTE: NOT ALL POTENTIAL AND/OR EXISTING HAZARDS WERE ANALYZED. THIS CERTIFICATE OF ANALYSIS IS RELEVANT ONLY TO THOSE ITEMS TESTED. THE SAMPLE WAS PROVIDED TO THE LABORATORY FOR TESTING BY THE CLIENT AND THE SAMPLE WAS TESTED AS RECEIVED.

END OF REPORT

